Search
Novo Nordisk to Launch Phase III Clinical Trial for Amycretin Weight Loss Treatment in Q1 2026
1 week ago /
Read about 0 minute
Author：小编
Novo Nordisk is set to commence the Phase III clinical trial for its innovative weight loss treatment, Amycretin, in the first quarter of 2026. Amycretin, a long-acting dual-target receptor agonist of GLP-1 and Amylin, has demonstrated superior efficacy in previous studies compared to Cagrilintide and is poised to compete with Eli Lilly's new triple-target drug, Retatrutide. This positions Amycretin as a significant player in the development of advanced weight loss medications. By reducing hunger and enhancing feelings of fullness, Amycretin aims to assist patients in achieving their weight loss goals.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
